Name in SEC filings: NEONC TECHNOLOGIES HOLDINGS, INC.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| NEO100-01 | Other | Phase 2 | by September 2025 | 8-K · |
| NEO212-01 | /data readout | Other | Wednesday, March 4, 2026, at 9:00 a.m. Eastern Time | 8-K · |
| NEO212 | FDA meeting | Phase 1 | July 9, 2026 | 8-K · |
| NEO100-01 | Topline/data readout | Phase 2 | August 12, 2026 | 8-K · |
| Registered direct offering | Other | Stage not stated | September 10, 2026 | 8-K · |
| NEO212 | FDA meeting | Phase 1 | November 17, 2026 | 8-K · |
Source: ORION, orionbiotechai.com/company/NTHI, data as of Oct 14, 2026
https://www.orionbiotechai.com/company/NTHI
NEO212 · FDA meeting · November 17, 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Otherby September 2025
Stage: Phase 2SEC filing · “Phase 2a”
Public float: $67,900,000 · as of · SEC filing
Full Phase 2a enrollment expected by September 2025.
SEC timing context:
NEO100-01 – Intranasal therapy for malignant gliomas
8-K · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2025-09)
Topline/data readoutWednesday, March 4, 2026, at 9:00 a.m. Eastern Time
Stage: OtherSEC filing · “Phase 1; Phase 1/2”
Public float: $67,900,000 · as of · SEC filing
On February 27, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that it will host an investor conference call and webcast on Wednesday, March 4, 2026, at 9:00 a.m. Eastern Time to present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial.
8-K · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-03)
FDA meetingJuly 9, 2026
Meeting date, not a results announcement
Stage: Phase 1SEC filing · “Phase 1”
Public float: $67,900,000 · as of · SEC filing
The written feedback was provided in advance of a Type B End-of-Phase 1 meeting scheduled for July 9, 2026.
SEC timing context:
CALABASAS, Calif., July 15, 2026 — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the chemistry, manufacturing and controls (“CMC”) development program for NEO212, the Company’s novel temozolomide-perillyl alcohol conjugate.
8-K · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-07)
Topline/data readoutAugust 12, 2026
Stage: Phase 2SEC filing · “Phase 2a”
Public float: $67,900,000 · as of · SEC filing
On August 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting second quarter financial results and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026.
8-K · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-08)
OtherSeptember 10, 2026
Stage: Not stated
Public float: $67,900,000 · as of · SEC filing
The Offering is expected to close on September 10, 2026, subject to the satisfaction of customary closing conditions (the “Closing Date”).
8-K · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-09)
FDA meetingNovember 17, 2026
Meeting date, not a results announcement
Stage: Phase 1SEC filing · “Phase 1”
Public float: $67,900,000 · as of · SEC filing
On September 28, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that it is scheduled to meet with the U.S. Food and Drug Administration on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-11)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| NEO212Other | November 17, 2026“On September 28, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that it is scheduled to meet with the U.S. Food and Drug Administration on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212.” Filed · 8-K | Period not started The stated period has not started yet, so there is nothing to compare. |
| Registered direct offeringOther | September 10, 2026“The Offering is expected to close on September 10, 2026, subject to the satisfaction of customary closing conditions (the “Closing Date”).” Filed · 8-K | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| NEO100-01Clinical results | August 12, 2026“On August 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting second quarter financial results and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026.” Filed · 8-K | Disclosure present SEC filing date within the stated period Filed · EX-99.1 “CALABASAS, Calif., August 12, 2026 – NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced positive topline results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100™ (purified perillyl alcohol) in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.” |
| NEO212Other | July 9, 2026“The written feedback was provided in advance of a Type B End-of-Phase 1 meeting scheduled for July 9, 2026.” Filed · EX-99.1 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| NEO100-01Clinical results | by the end of July 2026“The Company expects to report top-line data from the fully enrolled NEO100-01 Phase 2a trial by the end of July 2026, representing what NeOnc believes may be one of the most important clinical milestones in the Company’s history.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| NEO212-01Clinical results | Wednesday, March 4, 2026, at 9:00 a.m. Eastern Time“On February 27, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that it will host an investor conference call and webcast on Wednesday, March 4, 2026, at 9:00 a.m. Eastern Time to present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial.” Filed · 8-K | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| NEO100-01Clinical results | May 2026“Top-line data readout anticipated in May 2026” Filed · EX-99.1 | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| NEO100-01Other | by September 2025“Full Phase 2a enrollment expected by September 2025.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| NEO100-01Clinical results | early 2026“Top-line data readout anticipated in early 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for NTHI. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See NTHI in the calendar · Review labels and methodology